Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 101–200 of 1,000

Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications
Münzel, T., Gori, T., Keaney, J. F., Maack, C., & Daiber, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv305 · Cited by 394
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
Rouleau, J. L., Pfeffer, M. A., Stewart, D. J., Isaac, D., Sestier, F., Kerut, E. K., Porter, C., Proulx, G., Qian, C., & Block, A. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02602-7 · Cited by 391
Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction
Maisel, A. S., Koon, J., Krishnaswamy, P., Kazenegra, R., Clopton, P., Gardetto, N. J., Morrisey, R., Garcia, A., Chiu, A., & DeMaria, A. N. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113215 · Cited by 377
Diuretic resistance predicts mortality in patients with advanced heart failure
Neuberg, G. W., Miller, A. B., O’Connor, C., Belkin, R. N., Carson, P. E., Cropp, A. B., Frid, D. J., Nye, R., Pressler, M. L., WERTHEIMER, J. H., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123144 · Cited by 374
Self-citation
Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis
Salmon, P., Peters, S., & Stanley, I. M. (1999) · BMJ · doi:10.1136/bmj.318.7180.372 · Cited by 370
Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
Terry, K. W., Kam, K. K., Yan, B. P., & Lam, Y. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00750.x · Cited by 370
The treatment of heart failure: The Task Force of the Working Group on Heart Failure of the European Society of Cardiology
Remme, W. J., Cleland, J. G. F., Dargie, H. J., Erdmann, E., Ferrari, R., Kjekshus, J., Michel Komajda, N., Poole-Wilson, P. A., Riegger, G. A. J., Soler‐Soler, J., et al. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015339 · Cited by 362
Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure
Floras, J. S. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90466-e · Cited by 360
Noninvasive determination of aortic input impedance and external left ventricular power output: A validation and repeatability study of a new technique
Kelly, R. P., & Fitchett, D. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90198-v · Cited by 358
Effect of Beta-Blockade on Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Clinical Trials
Heidenreich, P. A., Lee, T. T., & Massie, B. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00104-6 · Cited by 357
Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril
Cohn, J. N., Ziesche, S., Smith, R. F., Anand, I. S., Dunkman, W. B., Loeb, H. S., Cintron, G. B., Boden, W. E., Baruch, L., Rochin, P., et al. (1997) · Circulation · doi:10.1161/01.cir.96.3.856 · Cited by 357
Self-citation
Impairment of Ventilatory Efficiency in Heart Failure
Kleber, F. X., Vietzke, G., Wernecke, K. D., Bauer, U. M. M., Opitz, C. F., Wensel, R., Sperfeld, A., & Gläser, S. (2000) · Circulation · doi:10.1161/01.cir.101.24.2803 · Cited by 355
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials
Bangalore, S., Kumar, S., Kjeldsen, S. E., Makani, H. J., Grossman, E., Wetterslev, J., Gupta, A. K., Sever, P., Gluud, C. N., & Messerli, F. H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70260-6 · Cited by 356
Diabetic cardiomyopathy: mechanisms, diagnosis and treatment
Hayat, S. A., Patel, B., Khattar, R. S., & Malik, R. A. (2004) · Clinical Science · doi:10.1042/cs20040057 · Cited by 353
A Comprehensive Management System for Heart Failure Improves Clinical Outcomes and Reduces Medical Resource Utilization
West, J. A., Miller, N. H., Parker, K. M., Senneca, D., Ghandour, G., Clark, M., Greenwald, G., Heller, R. S., Fowler, M. B., & DeBusk, R. F. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00676-5 · Cited by 341
Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy
Stelken, A. M., Younis, L. T., Jennison, S. H., Miller, D. D., Miller, L. W., Shaw, L. J., Kargl, D., & CHAITMAN, B. R. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00464-5 · Cited by 342
Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils
Nguyen, T. P., Qu, Z., & Weiss, J. N. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.10.018 · Cited by 336
Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death
Uretsky, B. F., Thygesen, K. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Packer, M., Poole-Wilson, P. A., & Rydén, L. (2000) · Circulation · doi:10.1161/01.cir.102.6.611 · Cited by 336
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction
Zile, M. R., Gaasch, W. H., Anand, I. S., Haass, M., Little, W. C., Miller, A. B., Lopez-Sendon, J. L., Teerlink, J. R., White, M., McMurray, J. J. V., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.909614 · Cited by 334
Self-citation
Effects of Continuous Positive Airway Pressure on Obstructive Sleep Apnea and Left Ventricular Afterload in Patients With Heart Failure
Tkáčová, R., Rankin, F., Fitzgerald, F. S., Floras, J. S., & Bradley, T. D. (1998) · Circulation · doi:10.1161/01.cir.98.21.2269 · Cited by 331
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Changing epidemiological features of cardiac failure
Kannel, W. B., Ho, K. K. L., & Thom, T. (1994) · Heart · doi:10.1136/hrt.72.2_suppl.s3 · Cited by 330
Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure
Lucas, C., Johnson, W. S., Hamilton, M. A., Fonarow, G. C., Woo, M. A., Flavell, C. M., Creaser, J. A., & Stevenson, L. W. (2000) · American Heart Journal · doi:10.1067/mhj.2000.110933 · Cited by 333
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology
Lopez-Sendon, J. L., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 331
The Management of Chronic Heart Failure
Cohn, J. N. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350707 · Cited by 328
Self-citation
Acute Hemodynamic Improvement by Thermal Vasodilation in Congestive Heart Failure
Tei, C., Horikiri, Y., Park, J.-C., Jeong, J., Chang, K.-S., Toyama, Y., & Tanaka, N. (1995) · Circulation · doi:10.1161/01.cir.91.10.2582 · Cited by 329
Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy
Fairweather, D., Cooper, L. T., & Blauwet, L. A. (2013) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.003 · Cited by 325
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Münzel, T. F., Kurz, S. D., Rajagopalan, S., Thoenes, M., Berrington, W. R., Thompson, J. A., Freeman, B. Α., & Harrison, D. G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118935 · Cited by 313
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
Lerman, A., Gibbons, R. J., Rodeheffer, R. J., Bailey, K. R., McKinley, L. J., Heublein, D. M., & Burnett, J. C. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)93125-k · Cited by 313
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.023 · Cited by 319
Self-citation
Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
Eichhorn, E. J., Heesch, C. M., Barnett, J. H., Alvarez, L. G., Fass, S. M., Grayburn, P. A., Hatfield, B. A., Marcoux, L., & Malloy, C. R. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90114-7 · Cited by 305
The economic burden of heart failure
O'Connell, J. B. (2000) · Clinical Cardiology · doi:10.1002/clc.4960231503 · Cited by 302
Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes
Yokoshiki, H., Katsube, Y., Sunagawa, M., & Sperelakis, N. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01108-4 · Cited by 302
Heart and Lung Transplantation Developed in Collaboration With the International Society for Guidelines Cardiology Foundation/American Heart Association Task Force on Practice Management of Heart Failure in Adults: A Report of the American College of 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and
Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Abraham, W. T., Casey, D. E., Feldman, A. M., & Ma, G. S. (2009) · Cited by 297
Structural Basis for Heart Failure
Cohn, J. N. (1995) · Circulation · doi:10.1161/01.cir.91.10.2504 · Cited by 295
Self-citation
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure
Doehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J. S., & Anker, S. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.093 · Cited by 294
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 302
A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study
Holubarsch, C., Rohrbach, M., Karrasch, M., Boehm, E., Poloński, L., Ponikowski, P. P., & Rhein, S. (2007) · Clinical Science · doi:10.1042/cs20060307 · Cited by 295
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
Task force 3: Recipient guidelines/prioritization
Mudge, G. H., Goldstein, S., Addonizio, L. J., Caplan, A. L., MANCINI, D. M., Levine, T. B., Ritsch, M. E., & Stevenson, L. W. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90812-f · Cited by 279
Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis
Khot, U. N., Novaro, G. M., Popović, Z., Mills, R. M., Thomas, J. D., Tuzcu, E. M., HAMMER, D. F., Nissen, S. E., & Francis, G. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022021 · Cited by 277
Self-citation
Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure
Chua, T. P., Clark, A. I., Amadi, A. A., & Coats, A. J. S. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00523-4 · Cited by 279
Prolonged Beneficial Effects of a Home-Based Intervention on Unplanned Readmissions and Mortality Among Patients With Congestive Heart Failure
Stewart, S., Vandenbroek, A. J., Pearson, S., & Horowitz, J. D. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.257 · Cited by 275
Angiotensin Receptors and Their Therapeutic Implications
Greindling, K. K., Lassegue, B. P., & Alexander, R. W. (1996) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001433 · Cited by 274
Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure.
Bonneux, L., Barendregt, J. J., Meeter, K., Bonsel, G. J., & van der Maas, P. J. (1994) · American Journal of Public Health · doi:10.2105/ajph.84.1.20 · Cited by 275
Clinical, Hemodynamic, and Cardiopulmonary Exercise Test Determinants of Survival in Patients Referred for Evaluation of Heart Failure
MYERS, J. N., Gullestad, L. L., Vagelos, R. H., Do, D., Bellin, D., Ross, H. J., & Fowler, M. B. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-4-199808150-00004 · Cited by 271
Potassium channel down-regulation in heart failure
Näbauer, M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00274-5 · Cited by 269
Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.
Brink, M., Wellen, J. J., & Delafontaine, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118698 · Cited by 266
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data
Dzau, V. J., Bernstein, K. E., Celermajer, D. S., Cohen, J. D., Dahlöf, B., Deanfield, J. E., Díez, J., Drexler, H., Ferrari, R., van Gilst, W. H., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 262
Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction
DOMANSKI, M. J., Mitchell, G. F., Norman, J. E., Exner, D. V., Pitt, B., & Pfeffer, M. A. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00679-2 · Cited by 262
Anemia as a risk factor and therapeutic target in heart failure
Felker, G. M., Adams, K. F., Gattis, W. A., & O'Connor, C. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.070 · Cited by 255
Task force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management
Califf, R. M., Armstrong, P. W., Carver, J. R., D’Agostino, R. B., & Strauss, W. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)87733-3 · Cited by 257
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B. R., Lamm, D. L., O’Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 255
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 251
The Primary and Secondary Prevention of Coronary Artery Disease
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M. D., O’Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., & Harrington, R. A. (2008) · CHEST Journal · doi:10.1378/chest.08-0685 · Cited by 250
Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction
Givertz, M. M., Stevenson, L. W., Costanzo, M. R., Bourge, R. C., Bauman, J. G., Ginn, G., & Abraham, W. T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.010 · Cited by 253
Angiotensin II, adhesion, and cardiac fibrosis
Schnee, J. M. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00044-4 · Cited by 256
ACE Inhibitor Use in Patients With Myocardial Infarction
Latini, R., Maggioni, A. P., Flather, M. D., Sleight, P., & Tognoni, G. (1995) · Circulation · doi:10.1161/01.cir.92.10.3132 · Cited by 249
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study
Wong, M., Staszewsky, L. I., Latini, R., Barlera, S., Volpi, A., Chiang, Y., Benza, R. L., Gottlieb, S. O., Kleemann, T., Rosconi, F., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02063-6 · Cited by 249
Self-citation
Rationale and Design of the GISSI Heart Failure Trial: A Large Trial to Assess the Effects of n-3 Polyunsaturated Fatty Acids and Rosuvastatin in Symptomatic Congestive Heart Failure
Tavazzi, L., Tognoni, G., Franzosi, M. G., Latini, R., Maggioni, A. P., Marchioli, R., Nicolosi, G. L., & Porcu, M. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.001 · Cited by 240
Diagnosis and Treatment of Heart Failure Based on Left Ventricular Systolic or Diastolic Dysfunction
Gaasch, W. H. (1994) · JAMA · doi:10.1001/jama.1994.03510400062033 · Cited by 240
Heart Failure Survival Among Older Adults in the United States
Croft, J. B., Giles, W. H., Pollard, R. A., Keenan, N. L., Casper, M. L., & Anda, R. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.505 · Cited by 240
Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors
Philbin, E. F., Rocco, T. A., Lindenmuth, N. W., Ulrich, K., & Jenkins, P. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00601-x · Cited by 238
Reverse remodeling in heart failure—mechanisms and therapeutic opportunities
Koitabashi, N., & Kass, D. A. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.172 · Cited by 241
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
Hall, D., Zeitler, H., & Rudolph, W. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90449-w · Cited by 235
Chronic Heart Failure: Contemporary Diagnosis and Management
Ramani, G. V., Uber, P. A., & Mehra, M. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0494 · Cited by 243
Failure to Improve Left Ventricular Function After Coronary Revascularization for Ischemic Cardiomyopathy Is Not Associated With Worse Outcome
Samady, H., Elefteriades, J. A., Abbott, B., Mattera, J. A., McPherson, C. A., & Wackers, F. J. T. (1999) · Circulation · doi:10.1161/01.cir.100.12.1298 · Cited by 235
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure
Binkley, P. F., Haas, G. J., Starling, R. C., Nunziata, E., Hatton, P. A., Leier, C. V., & Cody, R. J. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90098-l · Cited by 233
Nonallergic angioedema: role of bradykinin
Baş, M., Adams, V., Suvorava, T., Niehues, T., Hoffmann, T. K., & Kojda, G. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01427.x · Cited by 234
Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure
Steimle, A. E., Stevenson, L. W., Chelimsky-Fallick, C., Fonarow, G. C., Hamilton, M. A., Moriguchi, J. D., Kartashov, A. I., & Tillisch, J. H. (1997) · Circulation · doi:10.1161/01.cir.96.4.1165 · Cited by 230
Mode of Death in Advanced Heart Failure
Carson, P. E., Anand, I. S., O’Connor, C. J., Jaski, B. E., Steinberg, J. S., Lwin, A., Lindenfeld, J., Ghali, J., Barnet, J. H., Feldman, A. M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.016 · Cited by 231
Self-citation
International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children
Rosenthal, D. N., Chrisant, M., Edens, E., Mahony, L., Canter, C. E., Colan, S. D., Dubin, A. M., Lamour, J. M., Ross, R. D., Shaddy, R. E., et al. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.03.018 · Cited by 226
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
Struthers, A. D. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80009-1 · Cited by 228
Growth Hormone Improves Cardiac Performance in Experimental Heart Failure
Yang, R., Bunting, S., Gillett, N. A., CLARK, R. G., & Jin, H. (1995) · Circulation · doi:10.1161/01.cir.92.2.262 · Cited by 227
Improving survival for patients with advanced heart failure: A study of 737 consecutive patients
Stevenson, W. G., Stevenson, L. W., Middlekauff, H. R., Fonarow, G. C., Hamilton, M. A., Woo, M. A., Saxon, L. A., Natterson, P. D., Steimle, A. E., Walden, J. A., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00341-x · Cited by 220
Sodium Nitroprusside for Advanced Low-Output Heart Failure
Müllens, W., Abrahams, Z., Francis, G. S., Skouri, H. N., Starling, R. C., Young, J. B., Taylor, D. O., & Tang, W. H. W. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.083 · Cited by 224
Self-citation
Improving survival for patients with atrial fibrillation and advanced heart failure
Stevenson, W. G., Stevenson, L. W., Middlekauff, H. R., Fonarow, G. C., Hamilton, M. A., Woo, M. A., Saxon, L. A., Natterson, P. D., Steimle, A. E., Walden, J. A., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00358-0 · Cited by 218
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follmann, D., Ghali, J. K., Gilbert, E., Haffner, S., Katz, R., Lindenfeld, J., Lowes, B. D., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00856-8 · Cited by 215
Quality of Care by Race and Gender for Congestive Heart Failure and Pneumonia
Ayanian, J. Z., Weissman, J. S., Chasan-Taber, S., & Epstein, A. M. (1999) · Medical Care · doi:10.1097/00005650-199912000-00009 · Cited by 215
Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure
Massie, B. M., Fisher, S. G., DEEDWANIA, P. C., Singh, B. N., Fletcher, R. D., & Singh, S. N. (1996) · Circulation · doi:10.1161/01.cir.93.12.2128 · Cited by 215
Self-citation
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
Jessup, M. L., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Rahko, P. S., Silver, M. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.009 · Cited by 221
Self-citation
Heart failure: a growing public health problem
Eriksson, H. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01153.x · Cited by 216
Influence of diabetes mellitus on heart failure risk and outcome
Bauters, C., Lamblin, N., Fadden, E. P. M., BELLE, E. V., Millaire, A., & de Groote, P. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-1 · Cited by 214
Comparison of Surgical and Medical Group Survival in Patients With Left Main Equivalent Coronary Artery Disease
Caracciolo, E. A., Davis, K. B., Sopko, G. S., Kaiser, G. C., Corley, S. D., Schaff, H. V., Taylor, H. A., & CHAITMAN, B. R. (1995) · Circulation · doi:10.1161/01.cir.91.9.2335 · Cited by 211
Synthesis of isosorbide: an overview of challenging reactions
Dussenne, C., Delaunay, T., Wiatz, V., Wyart, H., Suisse, I., & Sauthier, M. (2017) · Green Chemistry · doi:10.1039/c7gc01912b · Cited by 209
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies
Voulgari, Tentolouris, N., & Papadogiannis, D. E. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 211
The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure
McKelvie, R. S., Moe, G. W., Ezekowitz, J. A., Heckman, G. A., Costigan, J., Ducharme, A., Estrella-Holder, E., Giannetti, N., Grzeslo, A., Harkness, K., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.10.007 · Cited by 208
Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy
Hochleitner, M., Hörtnagl, H., Hörtnagl, H., Fridrich, L., & Gschnitzer, F. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90769-u · Cited by 206
The Renin-Angiotensin-Aldosterone System and Heart Failure
SAYER, G. T., & Bhat, G. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.002 · Cited by 216
Self-citation
Antithrombotic Therapy for Coronary Artery Disease
Harrington, R. A., Becker, R. C., Ezekowitz, M. D., Meade, T. W., O’Connor, C. M., Vorchheimer, D. A., & Guyatt, G. H. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.513s · Cited by 204
?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
Pitt, B. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877755 · Cited by 207
Mode of death in chronic heart failure: A request and proposition for more accurate classification
Narang, R., Cleland, J. G. F., Erhardt, L., Ball, S., Coats, A. J. S., Cowley, A., Dargie, H. J., Hall, A. S., Hampton, J. R., & Poole-Wilson, A. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015074 · Cited by 203
ABC of heart failure: History and epidemiology
Davis, R. (2000) · BMJ · doi:10.1136/bmj.320.7226.39 · Cited by 200
Combination diuretic treatment in severe heart failure: a randomised controlled trial.
Channer, K. S., McLean, K. A., Lawson-Matthew, P. J., & Richardson, M. (1994) · Heart · doi:10.1136/hrt.71.2.146 · Cited by 199
Heart Failure in Women
Hsich, E., & Piña, I. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.066 · Cited by 197
Neuroendocrine activation in heart failure is modified by endurance exercise training
Braith, R. W., Welsch, M. A., Feigenbaum, M. S., Kluess, H. A., & Pepine, C. J. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00339-3 · Cited by 198
Fortnightly Review: Diagnosis and management of heart failure
Dargie, H. J., & McMurray, J. J. V. (1994) · BMJ · doi:10.1136/bmj.308.6924.321 · Cited by 197
Primary Prevention of Sudden Cardiac Death in Heart Failure: Will the Solution Be Shocking?
Uretsky, B. F., & Sheahan, R. G. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00361-6 · Cited by 197

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks